MCID: NRG002
MIFTS: 51

Neurogenic Bladder

Categories: Nephrological diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Bladder

MalaCards integrated aliases for Neurogenic Bladder:

Name: Neurogenic Bladder 12 30 6 15
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 45
Neurogenic Urinary Bladder 74
Neuropathic Bladder 12
Bladder Neurogenic 56

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 36 596.54
MeSH 45 D001750
NCIt 51 C79696
SNOMED-CT 69 23201000
UMLS 74 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to urofacial syndrome 1 and lethal congenital contracture syndrome 2, and has symptoms including seizures, vertigo and pain. An important gene associated with Neurogenic Bladder is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are Calcium signaling pathway and Arf6 trafficking events. The drugs Acetylcholine and Oxybutynin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, testes and prostate, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia : 77 Neurogenic bladder dysfunction, sometimes simply referred to as neurogenic bladder, is a dysfunction of... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 urofacial syndrome 1 32.2 HPSE2 LRIG2
2 lethal congenital contracture syndrome 2 31.9 ERBB3 PIP5K1C
3 hinman syndrome 11.7
4 polyglucosan body neuropathy, adult form 11.3
5 adult polyglucosan body disease 11.3
6 lethal congenital contracture syndrome 3 11.1
7 peroxisome biogenesis disorder 10b 11.1
8 leukodystrophy, progressive, early childhood-onset 11.1
9 spinal cord injury 10.7
10 myelomeningocele 10.5
11 multiple sclerosis 10.5
12 acute cystitis 10.5
13 vesicoureteral reflux 1 10.5
14 neural tube defects 10.4
15 bacteriuria 10.4
16 bladder disease 10.3
17 herpes zoster 10.2
18 cystitis 10.2
19 bladder cancer 10.1
20 cerebral palsy 10.1
21 lethal congenital contracture syndrome 10.1 ERBB3 PIP5K1C
22 systemic lupus erythematosus 10.0
23 pyelonephritis 10.0
24 neuropathy 10.0
25 lupus erythematosus 10.0
26 lethal congenital contracture syndrome 1 10.0 ERBB3 PIP5K1C
27 anus, imperforate 10.0
28 spinal stenosis 10.0
29 low compliance bladder 9.9 CHRM2 P2RX2
30 prostatic hyperplasia, benign 9.9
31 anxiety 9.9
32 legionnaire disease 9.9
33 chronic kidney failure 9.9
34 diabetes mellitus 9.9
35 sexual disorder 9.9
36 legionnaires' disease 9.9
37 legionellosis 9.9
38 prostatic hypertrophy 9.9
39 neurogenic bowel 9.9
40 bladder neck obstruction 9.9
41 interstitial cystitis 9.9
42 pyuria 9.9
43 impotence 9.9
44 spinal cord disease 9.9
45 kidney disease 9.9
46 paraplegia 9.9
47 arachnoid cysts 9.9
48 depression 9.9
49 encephalopathy 9.9
50 achondroplasia 9.8

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (show all 30)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Ischemic Heart Disease
Multiple Sclerosis Osteoporosis
Paralytic Ileus Paraplegia
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Prostatic Hypertrophy Protein-Energy Malnutrition
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


seizures, vertigo, pain, dysuria, meningism, reflex, abnormal, urgency of micturition, neurobehavioral manifestations, neuromuscular manifestations

MGI Mouse Phenotypes related to Neurogenic Bladder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.56 ACER3 CHRM2 ERBB3 GBE1 HPSE2 P2RX2
2 nervous system MP:0003631 9.23 ACER3 CHRM2 EBF3 ERBB3 GBE1 LRIG2

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
2
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Sulfamethoxazole Approved Phase 4,Phase 1,Phase 2 723-46-6 5329
5
Trimethoprim Approved, Vet_approved Phase 4,Phase 1,Phase 2 738-70-5 5578
6
Silodosin Approved Phase 4 160970-54-7
7
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
8
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Fosfomycin Approved Phase 4 23155-02-4 446987
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
13 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
14 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
16 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Not Applicable
19 Anesthetics Phase 4
20 Adrenergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
21 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
22 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Adrenergic alpha-Antagonists Phase 4,Phase 2,Phase 3,Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Antitubercular Agents Phase 4,Phase 1,Phase 2
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
33 Mandelic Acids Phase 4,Phase 3,Phase 2,Not Applicable
34 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Solifenacin succinate Phase 4 242478-38-2
36
Tamsulosin Approved, Investigational Phase 2, Phase 3,Phase 1 106133-20-4 129211
37
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
38
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
39
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
40 Cranberry Approved, Investigational Phase 3
41
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
42
Ofloxacin Approved Phase 3 82419-36-1 4583
43
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
44
Fesoterodine Approved Phase 3 286930-02-7, 286930-03-8 6918558
45
Mirabegron Approved Phase 2, Phase 3,Early Phase 1 223673-61-8 9865528
46
tannic acid Approved Phase 2, Phase 3 1401-55-4
47
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
48 Octenidine Investigational Phase 2, Phase 3 71251-02-0
49 Anti-Infective Agents, Local Phase 2, Phase 3,Not Applicable
50 carnitine Phase 3

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
2 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
3 Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4 silodosin
4 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
5 Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
6 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
7 Quality of Life Intermittent Catheter Study Completed NCT01523743 Phase 4
8 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4 Oxybutynin transdermal system
9 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome Completed NCT00277563 Phase 4
10 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder Recruiting NCT01192568 Phase 4 Oxybutynin
11 Antiseptic-coated Intermittent Urinary Catheter Unknown status NCT02697162 Phase 2, Phase 3 Octenidine chloride
12 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
13 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
14 Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3 Oxybutynin;Botulinum Toxin A injection
15 Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder Completed NCT00796614 Phase 2, Phase 3 tamsulosin hydrochloride;Placebo
16 Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction Completed NCT00549939 Phase 3 Alfuzosin;Placebo
17 Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology Completed NCT00576823 Phase 3 Alfuzosin
18 Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3 alfuzosin (SL770499)
19 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
20 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
21 Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
22 Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients Completed NCT00280592 Phase 3 Cranberry;Placebo
23 A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections Completed NCT00258089 Phase 3 Levofloxacin
24 A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Recruiting NCT01557244 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine PR 8 mg;Oxybutynin;Fesoterodine PR;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
25 Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury Active, not recruiting NCT03503513 Phase 2, Phase 3 Gentamicin Sulfate;Saline
26 Vaginal Estriol in Multiple Sclerosis Not yet recruiting NCT03774407 Phase 2, Phase 3 vaginal estriol
27 Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients Terminated NCT02044510 Phase 2, Phase 3 Mirabegron;Placebo
28 Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) Unknown status NCT02591901 Phase 2 Uro vaxom
29 Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder Unknown status NCT02044965 Phase 1, Phase 2 Probiotic
30 Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization Unknown status NCT01305681 Phase 1, Phase 2
31 Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction Unknown status NCT00602186 Phase 1, Phase 2 tamsolusin;prazosin
32 PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder Completed NCT00340704 Phase 2 tamsulosin hydrochloride
33 Self Management in Urinary Catheter Users Completed NCT00883220 Phase 2
34 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed NCT00732238 Phase 2
35 Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation Completed NCT01243125 Phase 2 NVC-422, 0.2%;Sterile normal saline, 0.9%
36 Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury Not yet recruiting NCT03187795 Phase 2 Oxybutynin Chloride IR;Mirabegron
37 Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury Terminated NCT00512148 Phase 2
38 Augmentation Cystoplasty Using an Autologous Neo-Bladder Terminated NCT00419120 Phase 2
39 Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344) Terminated NCT00711087 Phase 2 BOTOX-A
40 NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder Terminated NCT00213577 Phase 2 type A botulinum toxin
41 Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Terminated NCT01598103 Phase 2 SAF312;Placebo to SAF312
42 Bacteriuria Eradication Through Probiotics Unknown status NCT00717600 Phase 1
43 Colonizing Neurogenic Bladders With Benign Flora Completed NCT00371631 Phase 1
44 Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution Completed NCT01429090 Phase 1 Vagantin®;methantheline solution
45 E. Coli for Prevention of Catheter UTI in SCI Patients Completed NCT00458471 Phase 1
46 Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia Completed NCT01909154 Phase 1
47 Gene Expression in the Overactive Bladder in Children Unknown status NCT02086058
48 Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy Unknown status NCT02059798
49 Sterile Single-use vs Reused Polyvinylchloride Catheter For Intermittent Catheterization In Neurogenic Bladder Completed NCT03424499 Not Applicable
50 Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Completed NCT01299792

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

# Genetic test Affiliating Genes
1 Neurogenic Bladder 30

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

42
Spinal Cord, Testes, Prostate, Brain, Kidney, Colon, Bone Marrow

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(show top 50) (show all 1140)
# Title Authors Year
1
Reliability and Validity of the Neurogenic Bladder Symptom Score in Adults with Cerebral Palsy. ( 30890419 )
2019
2
Parkinsonian GM2 synthase knockout mice lacking mature gangliosides develop urinary dysfunction and neurogenic bladder. ( 30393144 )
2019
3
Re: Long-Term Effectiveness and Complication Rates of Bladder Augmentation in Patients with Neurogenic Bladder Dysfunction: A Systematic Review. ( 30577384 )
2019
4
Biomarkers for the Diagnosis and Prognosis of Neurogenic Bladder-Is the Need Being Addressed? ( 30577387 )
2019
5
Epidural Analgesia Decreases Narcotic Requirements in Patients with Low Level Spina Bifida Undergoing Urological Laparotomy for Neurogenic Bladder and Bowel. ( 30577407 )
2019
6
Antibiotic Prophylaxis for UTIs in Patients with Neurogenic Bladder. ( 30702262 )
2019
7
Validity of a disposable catheter to drain urine overnight in neurogenic bladder. ( 30779413 )
2019
8
Effect of continuous care intervention on the quality of life in patients with neurogenic bladder dysfunction. ( 30880527 )
2019
9
Urinary tract infections in patients with neurogenic bladder. ( 30885540 )
2019
10
Surgical management of the neurogenic bladder after spinal cord injury. ( 29680953 )
2018
11
Intraspinal schwannoma and neurogenic bladder. ( 29543054 )
2018
12
The ability of prior urinary cultures results to predict future culture results in neurogenic bladder patients. ( 29799144 )
2018
13
Surgical Management of Anatomic Bladder Outlet Obstruction in Males with Neurogenic Bladder Dysfunction: A Systematic Review. ( 29551557 )
2018
14
Characterization and in vivo efficacy of a heptapeptide ODT formulation for the treatment of neurogenic bladder dysfunction. ( 29195918 )
2018
15
De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer. ( 29504654 )
2018
16
Anatomical Feasibility of Extradural Transferring S2 and S3 Ventral Roots to S1 Ventral Root for Restoring Neurogenic Bladder in Spinal Cord Injury. ( 29470276 )
2018
17
Re: Quality of Life after Suprapubic Catheter Placement in Patients with Neurogenic Bladder Conditions. ( 29310196 )
2018
18
Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injury. ( 29569211 )
2018
19
Clinical outcomes of non-surgical management of detrusor leak point pressures above 40a88cm water in adults with congenital neurogenic bladder. ( 29488655 )
2018
20
Neurogenic bladder findings in patients with Congenital Zika Syndrome: A novel condition. ( 29494684 )
2018
21
Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson's disease and multiple system atrophy. ( 29356135 )
2018
22
Vesical fungus balls (fungal bezoars) by <i>Candida albicans</i> mimicking urothelial carcinoma in a patient with diabetic neurogenic bladder. ( 29556476 )
2018
23
Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. ( 29752515 )
2018
24
Analysis of bladder cancer subtypes in neurogenic bladder tumors. ( 29524970 )
2018
25
Current and future international patterns of care of neurogenic bladder after spinal cord injury. ( 29605828 )
2018
26
Evaluating a telehealth intervention for urinalysis monitoring in children with neurogenic bladder. ( 29804471 )
2018
27
Application of clean intermittent catheterization for neurogenic bladder in infants less than 1 year old. ( 29660959 )
2018
28
Posterior Reversible Encephalopathy Syndrome after Augmentation Cystoplasty in a Child with Neurogenic Bladder. ( 30050267 )
2018
29
The role of appetite-regulating hormones: Ghrelin and leptin in the nutritional status of children with neurogenic bladder due to myelomeningocele. ( 30488610 )
2018
30
A cross-sectional study of the catheter management of neurogenic bladder after traumatic spinal cord injury. ( 28580635 )
2018
31
Non-surgical urologic management of neurogenic bladder after spinal cord injury. ( 30051263 )
2018
32
TGF-β1 and connexin-43 expression in neurogenic bladder from rats with sacral spinal cord injury. ( 30070388 )
2018
33
Misplaced Foley catheter in ureter in a female with neurogenic bladder: a rare complication report. ( 30121570 )
2018
34
A Proof-of-Concept Study of Transcutaneous Magnetic Spinal Cord Stimulation for Neurogenic Bladder. ( 30135433 )
2018
35
A Review of Botulinum Toxin A for the Treatment of Neurogenic Bladder. ( 30138720 )
2018
36
Preventing urinary tract infections in patients with neurogenic bladder. ( 30153930 )
2018
37
Protocol for a randomized clinical trial investigating early sacral nerve stimulation as an adjunct to standard neurogenic bladder management following acute spinal cord injury. ( 30157824 )
2018
38
A Retrospective Case Series of High-Frequency Spinal Cord Stimulation (HF10-SCS) in Neurogenic Bladder Incontinence. ( 30169840 )
2018
39
Ancillary benefits of bladder chemodenervation for SCI neurogenic bladder. ( 30245851 )
2018
40
Safety, Feasibility, and Efficacy of Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury Neurogenic Bladder: A Randomized Control Pilot Trial. ( 30284350 )
2018
41
Management of neurogenic bladder in patients with Parkinson's disease: A systematic review. ( 30407660 )
2018
42
Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. ( 30511212 )
2018
43
Lower urinary tract symptoms treatment constraints assessment (LUTS-TCA): a new tool for a global evaluation of neurogenic bladder treatments. ( 30511213 )
2018
44
Isolated Neurogenic Bladder Associated With Human T-Lymphotropic Virus Type 1 Infection in a Renal Transplant Patient From Central Australia: A Case Report. ( 30577291 )
2018
45
Electroacupuncture improves neurogenic bladder dysfunction through activation of NGF/TrkA signaling in a rat model. ( 30592331 )
2018
46
Neomycin-polymyxin or gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on clean intermittent catheterization. ( 30611650 )
2018
47
Applicability of botulinum toxin type A in paediatric neurogenic bladder management. ( 27748667 )
2017
48
Management of urinary tract infection with intravesical amikacin may increase the risk of bladder oxidative stress in children with neurogenic bladder. ( 28956280 )
2017
49
Application of data mining techniques to explore predictors of upper urinary tract damage in patients with neurogenic bladder. ( 28832768 )
2017
50
Re: Barriers to Transition in Young Adults with Neurogenic Bladder. ( 29144923 )
2017

Variations for Neurogenic Bladder

ClinVar genetic disease variations for Neurogenic Bladder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EBF3 NM_001005463.2(EBF3): c.512G> A (p.Gly171Asp) single nucleotide variant Pathogenic rs1057519437 GRCh37 Chromosome 10, 131755564: 131755564
2 EBF3 NM_001005463.2(EBF3): c.512G> A (p.Gly171Asp) single nucleotide variant Pathogenic rs1057519437 GRCh38 Chromosome 10, 129957300: 129957300
3 CACNA1A NM_001127221.1(CACNA1A): c.6128C> T (p.Thr2043Met) single nucleotide variant Uncertain significance rs563345694 GRCh37 Chromosome 19, 13323262: 13323262
4 CACNA1A NM_001127221.1(CACNA1A): c.6128C> T (p.Thr2043Met) single nucleotide variant Uncertain significance rs563345694 GRCh38 Chromosome 19, 13212448: 13212448
5 COL6A2 NM_001849.3(COL6A2): c.2008A> G (p.Thr670Ala) single nucleotide variant Uncertain significance GRCh37 Chromosome 21, 47545737: 47545737
6 COL6A2 NM_001849.3(COL6A2): c.2008A> G (p.Thr670Ala) single nucleotide variant Uncertain significance GRCh38 Chromosome 21, 46125823: 46125823

Expression for Neurogenic Bladder

Search GEO for disease gene expression data for Neurogenic Bladder.

Pathways for Neurogenic Bladder

Pathways related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.2 CHRM2 ERBB3 P2RX1 P2RX2
2 10.6 CHRM2 PIP5K1C

GO Terms for Neurogenic Bladder

Cellular components related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of postsynaptic membrane GO:0099055 8.96 CHRM2 P2RX1
2 integral component of nuclear inner membrane GO:0005639 8.62 P2RX1 P2RX2

Biological processes related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of synaptic vesicle exocytosis GO:2000300 9.32 CHRM2 P2RX1
2 cation transmembrane transport GO:0098655 9.26 P2RX1 P2RX2
3 regulation of smooth muscle contraction GO:0006940 9.16 CHRM2 P2RX1
4 response to ATP GO:0033198 8.96 P2RX1 P2RX2
5 purinergic nucleotide receptor signaling pathway GO:0035590 8.62 P2RX1 P2RX2

Molecular functions related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellularly ATP-gated cation channel activity GO:0004931 9.16 P2RX1 P2RX2
2 ATP-gated ion channel activity GO:0035381 8.96 P2RX1 P2RX2
3 purinergic nucleotide receptor activity GO:0001614 8.62 P2RX1 P2RX2

Sources for Neurogenic Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....